Matveï Apraxine
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Matveï Apraxine has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Antoine Froidure
Pole of Lung, Nose and Skin research (LUNS), Institut de Recherche Expérimentale et Clinique (IREC) UCLouvain, Brussels, Belgium
1 shared publication Astrid De Cuyper
Department of Oncology, Cliniques Universitaires Saint-Luc, Institut Roi Albert II, Brussels, Belgium
1 shared publicationBenoit Colinet
Dept of Pulmonology, GHdC, Charleroi, Belgium
1 shared publication- Françoise Pirson
Department of Pulmonary Medicine, Cliniques Universitaires Saint-Luc, 1200 Brussels, Belgium
1 shared publication Gabriela Beniuga
Institute of Pathology and Genetics, Charleroi, Belgium
1 shared publicationJean Huet
Dept of Otolaryngology, GHdC, Charleroi, Belgium
1 shared publication
Latest Publications
- Open Access
- 22 December 2022
- Published by Springer Nature in Allergy, Asthma & Clinical Immunology
- Vol. 18 (1) , 1-7
Hypersensitivity reactions to folinic acid: mechanisms involved based on two case reports and a literature review
Background: Hypersensitivity reactions (HSR) to antineoplastic agents are an increasing problem, especially when they lead to treatment discontinuation, sometimes without any equivalent therapeutic option. HSR to folinic acid (FA), used particularly for the treatment of digestive carcinoma along with oxaliplatin and 5-fluorouracil, are rare. Only seven publications report HSR to FA, mainly confirmed by the disappearance of symptoms after the withdrawal of FA from chemotherapy. Only two papers describe allergy testing. Due to the difficult diagnosis, patients usually receive several further cycles of chemotherapy with progressively more intense symptoms before the withdrawal of FA. Case presentation: Here we document two cases of HSR to FA, initially misattributed to oxaliplatin. The first patient described successive cycles with first back muscle pain, then chills and facial oedema and finally diffuse erythema with labial edema despite premedication. The allergy assessment highlighted high acute tryptase levels and intradermal tests positive for FA, pointing to an immunoglobulin E (IgE)-mediated mechanism. The second patient also had lower back muscle pain and chills in addition to tachycardia and desaturation during the administration of FA. Skin tests were negative and tryptase levels normal. After withdrawing FA, the symptoms did not recur, thus allowing the patient to continue chemotherapy. The mechanism of FA hypersensitivity is still unclear. The chronology of symptoms suggests an IgE-mediated mechanism that was not documented in the allergy assessment. A non-IgE-mediated mast cell/basophil activation could be involved, through complement activation or through Mas-related G protein-coupled receptors X2 (MRGPRX2) particularly. Conclusions: These two cases of anaphylaxis to FA document the clinical manifestations associated with two different mechanisms of HSR. This paper provided the opportunity to review the limited literature on HSR to FA. Through these cases, we hope to draw the practitioner’s attention to FA as a potential agent of severe hypersensitivity, especially if symptoms remain after withdrawing the most suspected chemotherapeutic agents. We want also to stress the importance of allergy testing.
- 22 December 2022
- Published by Springer Nature in Allergy, Asthma & Clinical Immunology
- Vol. 18 (1) , 1-7
Open AccessHypersensitivity reactions to folinic acid: mechanisms involved based on two case reports and a literature review
Background: Hypersensitivity reactions (HSR) to antineoplastic agents are an increasing problem, especially when they lead to treatment discontinuation, sometimes without any equivalent therapeutic option. HSR to folinic acid (FA), used particularly for the treatment of digestive carcinoma along with oxaliplatin and 5-fluorouracil, are rare. Only seven publications report HSR to FA, mainly confirmed by the disappearance of symptoms after the withdrawal of FA from chemotherapy. Only two papers describe allergy testing. Due to the difficult diagnosis, patients usually receive several further cycles of chemotherapy with progressively more intense symptoms before the withdrawal of FA. Case presentation: Here we document two cases of HSR to FA, initially misattributed to oxaliplatin. The first patient described successive cycles with first back muscle pain, then chills and facial oedema and finally diffuse erythema with labial edema despite premedication. The allergy assessment highlighted high acute tryptase levels and intradermal tests positive for FA, pointing to an immunoglobulin E (IgE)-mediated mechanism. The second patient also had lower back muscle pain and chills in addition to tachycardia and desaturation during the administration of FA. Skin tests were negative and tryptase levels normal. After withdrawing FA, the symptoms did not recur, thus allowing the patient to continue chemotherapy. The mechanism of FA hypersensitivity is still unclear. The chronology of symptoms suggests an IgE-mediated mechanism that was not documented in the allergy assessment. A non-IgE-mediated mast cell/basophil activation could be involved, through complement activation or through Mas-related G protein-coupled receptors X2 (MRGPRX2) particularly. Conclusions: These two cases of anaphylaxis to FA document the clinical manifestations associated with two different mechanisms of HSR. This paper provided the opportunity to review the limited literature on HSR to FA. Through these cases, we hope to draw the practitioner’s attention to FA as a potential agent of severe hypersensitivity, especially if symptoms remain after withdrawing the most suspected chemotherapeutic agents. We want also to stress the importance of allergy testing.
- Open Access
- 11 October 2022
- Published by European Respiratory Society (ERS) in Breathe
- Vol. 18 (3) , 220026
A breath of not so fresh air…
Despite being widely used as a recreational drug, “poppers” lack a legal framework for their delivery. Their composition may vary largely. This report describes a case of severe bronchiolitis following amyl nitrite mixture inhalation.https://bit.ly/3p3S7LM
- 11 October 2022
- Published by European Respiratory Society (ERS) in Breathe
- Vol. 18 (3) , 220026
Open AccessA breath of not so fresh air…
Despite being widely used as a recreational drug, “poppers” lack a legal framework for their delivery. Their composition may vary largely. This report describes a case of severe bronchiolitis following amyl nitrite mixture inhalation.https://bit.ly/3p3S7LM
- Open Access
- 1 June 2020
- Published by European Respiratory Society (ERS) in Breathe
- Vol. 16 (2) , 200006
An unusual progressive stridor
A flow–volume curve with a flattening of the inspiratory and expiratory limb suggests a proximal obstruction of the upper airways. Plasma cell neoplasms need to be considered in the differential diagnosis of an invasion of the upper respiratory tract.https://bit.ly/2K9lOXj
- 1 June 2020
- Published by European Respiratory Society (ERS) in Breathe
- Vol. 16 (2) , 200006
Open AccessAn unusual progressive stridor
A flow–volume curve with a flattening of the inspiratory and expiratory limb suggests a proximal obstruction of the upper airways. Plasma cell neoplasms need to be considered in the differential diagnosis of an invasion of the upper respiratory tract.https://bit.ly/2K9lOXj